AN6015

AN6015 is a preclinical small‑molecule or biologic drug candidate developed by Adlai Nortye that is listed among a portfolio of five proprietary compounds (AN4005, AN3025, AN0015, AN9015, and AN6015) for which the company has executed global license-out agreements, but whose specific target, modality, and indication have not been publicly disclosed. Available corporate and regulatory filings only identify AN6015 as a distinct investigational asset within Adlai Nortye’s oncology/immuno-oncology pipeline and as part of a right-and-interest transfer and global license deal, without revealing mechanism of action, molecular class, or clinical-stage use in any particular disease.